Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.
Sign Up to like & getrecommendations! Published in 2022 at "Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology"
DOI: 10.1002/wnan.1774
Abstract: Although a wide variety of topical microbicides provide promising in vitro and in vivo efficacy, most of them failed to prevent sexual transmission of human immunodeficiency virus type 1 (HIV-1) in human clinical trials. In… read more here.
Keywords: development; baseline time; clinical trials; preclinical development ... See more keywords
Immunophenotyping: analytical approaches and role in preclinical development of nanomedicines.
Sign Up to like & getrecommendations! Published in 2022 at "Advanced drug delivery reviews"
DOI: 10.1016/j.addr.2022.114281
Abstract: Pharmaceutical products can activate immune cells, suppress their function, or change the immune responses to traditional immunologically active agonists such as those present in microbes. Therefore, the assessment of immunostimulation, immunosuppression, and immunomodulation comprises the… read more here.
Keywords: preclinical development; approaches role; analytical approaches; role preclinical ... See more keywords
Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.7b01765
Abstract: Rohitukine (1), a chromone alkaloid isolated from Indian medicinal plant Dysoxylum binectariferum, has inspired the discovery of flavopiridol and riviciclib, both of which are bioavailable only via intravenous route. With the objective to address the… read more here.
Keywords: preclinical development; kinase; iiim 290; discovery ... See more keywords
Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Medicinal Chemistry"
DOI: 10.1021/acs.jmedchem.8b01218
Abstract: The leishmaniases are diseases that affect millions of people across the world, in particular visceral leishmaniasis (VL) which is fatal unless treated. Current standard of care for VL suffers from multiple issues and there is… read more here.
Keywords: preclinical development; candidate; visceral leishmaniasis; gsk3186899 ddd853651 ... See more keywords
Preclinical Development of Pentamidine Analogs Identifies a Potent and Nontoxic Antibiotic Adjuvant.
Sign Up to like & getrecommendations! Published in 2022 at "ACS infectious diseases"
DOI: 10.1021/acsinfecdis.1c00482
Abstract: The difficulty in treating Gram-negative bacteria can largely be attributed to their highly impermeable outer membrane (OM), which serves as a barrier to many otherwise active antibiotics. This can be overcome with the use of… read more here.
Keywords: development; preclinical development; pentamidine; antibiotic adjuvant ... See more keywords
Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics
Sign Up to like & getrecommendations! Published in 2022 at "Translational Psychiatry"
DOI: 10.1038/s41398-022-01904-2
Abstract: Despite 50+ years of drug discovery, current antipsychotics have limited efficacy against negative and cognitive symptoms of schizophrenia, and are ineffective—with the exception of clozapine—against any symptom domain for patients who are treatment resistant. Novel… read more here.
Keywords: preclinical development; efficacy; rodent models; treatment resistant ... See more keywords
Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-59711-y
Abstract: The vaccine elicitation of broadly neutralizing antibodies against HIV-1 is a long-sought goal. We previously reported the amino-terminal eight residues of the HIV-1-fusion peptide (FP8) – when conjugated to the carrier protein, keyhole limpet hemocyanin… read more here.
Keywords: vaccine immunogen; preclinical development; fusion peptide; carrier ... See more keywords
721 AT1412, a patient-derived CD9 antibody in preclinical development promoting tumor immune infiltration and inducing tumor rejection
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-sitc2020.0721
Abstract: Background Adaptive immunity to cancer cells forms a crucial part of cancer immunotherapy. Recently, the importance of tumor B-cell signatures were shown to correlate with melanoma survival. We investigated whether tumor-targeting antibodies could be isolated… read more here.
Keywords: melanoma; preclinical development; infiltration; rejection ... See more keywords
Abstract 710: Preclinical development of ALD2510, a Next-Gen Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody for the treatment of solid tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-710
Abstract: Within the tumor microenvironment (TME), TREGS have been associated with worse prognosis and/or resistance to checkpoint inhibitor (CPI) therapy in various cancer diseases, making these cells a promising target for the development of new immunotherapies.… read more here.
Keywords: development; anti cd25; preclinical development; cd25 antibody ... See more keywords
Abstract 6728: Preclinical development of QL325, a novel T cell engager targeting CLEC12A-positive AML
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-6728
Abstract: Despite advancement in targeted therapies, treatment options for patients with acute myeloid leukemia (AML) that provide a tolerable and durable response remain elusive. We have developed a CD3 bispecific antibody, QL325, targeting CLEC12A, a c-type… read more here.
Keywords: ql325 novel; targeting clec12a; cell; development ql325 ... See more keywords
Abstract 6875: Preclinical development of a novel small molecule multitarget inhibitor LCI133 for endometrial adenocarcinoma
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-6875
Abstract: Endometrial cancer (EC) is the most common gynecologic malignancy with rising mortality and limited targeted therapies. LCI133, an in silico-designed triple inhibitor of CDK4/6-CDK9-AURK, has demonstrated nano-molar potency against PTEN-mutant EC cells lines and favorable… read more here.
Keywords: cancer; pgr cre; inhibitor; endometrial adenocarcinoma ... See more keywords